Skip to content

Blue Blockers at Night and Insomnia Symptoms

Blocking Nocturnal Blue Light to Treat Insomnia: A Pilot Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02698800
Enrollment
15
Registered
2016-03-04
Start date
2016-03-31
Completion date
2017-03-31
Last updated
2019-07-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia, Sleep

Brief summary

Under entrained conditions, humans maintain a consolidated nocturnal sleep episode that coincides with environmental darkness and endogenous melatonin secretion. Various factors, such as artificial light, can compromise this temporal harmony, resulting in sleep disruption. Light is the strongest synchronizer of the circadian clock, with direct inputs via the retinohypothalamic tract to brain centers regulating sleep and circadian rhythms. Evening light exposure can suppress melatonin secretion and worsen sleep. This is critical, since most individuals routinely expose themselves to light before bedtime. The high sensitivity of the circadian system to blue wavelength light indicates that modern light sources such as light-emitting diodes (LED) may have particularly deleterious effects on sleep. It is possible to selectively filter out blue light while maintaining other visible spectra with blue-blocking (BB) lenses. Wearing BB lenses before bedtime may present a simple, affordable, and safe method to improve sleep. None have yet investigated the effects of BB lenses on subjective and objective sleep in insomnia patients, while simultaneously exploring the effects on melatonin secretion.

Detailed description

This study seeks to investigate the impact of BB lenses on melatonin and sleep in insomnia patients using a randomized, placebo-controlled crossover study, with the aim of developing a novel non-pharmacological approach for the treatment of insomnia. 15 individuals with insomnia will wear either BB or placebo (clear) lenses for 2 hours preceding bedtime while at home, for 1 week in a cross-over design. Sleep quality will be documented while at home, at also melatonin secretion while in the laboratory. It is predicted that compared to placebo, wearing BB lenses for 2 hours preceding bedtime will attenuate bright light associated melatonin suppression and improve sleep.

Interventions

DEVICEBlue blocking (BB) lenses

Participants will wear blue blocking lenses each night for 1 week for 2 hours preceding bedtime.

DEVICEClear lenses

Participants will wear clear lenses each night for 1 week for 2 hours preceding bedtime.

Sponsors

Columbia University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Insomnia for at least 1 month based on Insomnia Symptoms Questionnaire

Exclusion criteria

* obstructive sleep apnea; narcolepsy; periodic leg movement disorder * currently shift worker * psychiatric or neurologic disorders * deep vein thrombosis * current cigarette smoker * currently taking beta-blockers * pregnant/breastfeeding * children less than 1 year old at home * excessive daily caffeine intake

Design outcomes

Primary

MeasureTime frameDescription
Pittsburgh Insomnia Rating Scale-65 (PIRS65) Total ScoreAfter 7 nights of BB lensesPittsburgh Insomnia Rating Scale-65; measures the self-reported severity of insomnia over the past week. Higher scores indicate worsened severity. There are 65 items, each scored on a 4-point scale from low-high on symptom severity or frequency. There is a Total score, and 3 subscales: Distress score (how bothersome the sleep impairment is), Sleep Parameters score (sleep quality), and Quality of Life score. For the total score scoring is done by summing the scores from questions 1-65. Minimum Score=0 (good); Maximum Score=195 (bad) For the distress score, scoring is done by summing the scores from questions 1-46. Minimum Score=0 (not bothered); Maximum Score=138 (severely bothered) For the sleep parameters score, scoring is done by summing the scores from questions 47-56. Minimum Score=0 (good sleep); Maximum Score=30 (disrupted sleep) For the quality of life score, scoring is done by summing the scores from questions 57-65. Minimum Score=0 (excellent); Maximum Score=27 (poor)

Secondary

MeasureTime frameDescription
Sleep Efficiency (Time Spent Asleep Divided by Total Time in Bed) Determined With Wrist-worn AccelerometryAfter 7 nights of BB lensesWrist-worn accelerometry gives an estimate of time spent asleep, time spent in bed, and sleep efficiency can be calculated from this. Sleep efficiency is calculated as time spent asleep divided by total time in bed. Here, we considered the mean calculated sleep efficiency over each 7-day treatment period.

Countries

United States

Participant flow

Participants by arm

ArmCount
Blue Blocking (BB)/Clear
Wearing of BB lenses. Blue blocking (BB) lenses: Participants will wear blue blocking lenses each night for 1 week for 2 hours preceding bedtime. Clear lenses: Participants will wear clear lenses each night for 1 week for 2 hours preceding bedtime.
14
Total14

Baseline characteristics

CharacteristicBlue Blocking (BB)/Clear
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
14 Participants
Age, Continuous46.6 years
STANDARD_DEVIATION 11.5
Race/Ethnicity, Customized
Asian
2 Participants
Race/Ethnicity, Customized
Black/African American
6 Participants
Race/Ethnicity, Customized
White
6 Participants
Region of Enrollment
United States
14 participants
Sex: Female, Male
Female
8 Participants
Sex: Female, Male
Male
6 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 150 / 15
other
Total, other adverse events
0 / 150 / 15
serious
Total, serious adverse events
0 / 150 / 15

Outcome results

Primary

Pittsburgh Insomnia Rating Scale-65 (PIRS65) Total Score

Pittsburgh Insomnia Rating Scale-65; measures the self-reported severity of insomnia over the past week. Higher scores indicate worsened severity. There are 65 items, each scored on a 4-point scale from low-high on symptom severity or frequency. There is a Total score, and 3 subscales: Distress score (how bothersome the sleep impairment is), Sleep Parameters score (sleep quality), and Quality of Life score. For the total score scoring is done by summing the scores from questions 1-65. Minimum Score=0 (good); Maximum Score=195 (bad) For the distress score, scoring is done by summing the scores from questions 1-46. Minimum Score=0 (not bothered); Maximum Score=138 (severely bothered) For the sleep parameters score, scoring is done by summing the scores from questions 47-56. Minimum Score=0 (good sleep); Maximum Score=30 (disrupted sleep) For the quality of life score, scoring is done by summing the scores from questions 57-65. Minimum Score=0 (excellent); Maximum Score=27 (poor)

Time frame: After 7 nights of BB lenses

Population: Participants who completed both phases

ArmMeasureValue (MEAN)Dispersion
Blue Blocking (BB)Pittsburgh Insomnia Rating Scale-65 (PIRS65) Total Score72.64 units on a scaleStandard Deviation 28.14
Primary

Pittsburgh Insomnia Rating Scale-65 (PIRS65) Total Score

Pittsburgh Insomnia Rating Scale-65; measures the self-reported severity of insomnia over the past week. Higher scores indicate worsened severity. There are 65 items, each scored on a 4-point scale from low-high on symptom severity or frequency. There is a Total score, and 3 subscales: Distress score (how bothersome the sleep impairment is), Sleep Parameters score (sleep quality), and Quality of Life score. For the total score scoring is done by summing the scores from questions 1-65. Minimum Score=0 (good); Maximum Score=195 (bad) For the distress score, scoring is done by summing the scores from questions 1-46. Minimum Score=0 (not bothered); Maximum Score=138 (severely bothered) For the sleep parameters score, scoring is done by summing the scores from questions 47-56. Minimum Score=0 (good sleep); Maximum Score=30 (disrupted sleep) For the quality of life score, scoring is done by summing the scores from questions 57-65. Minimum Score=0 (excellent); Maximum Score=27 (poor)

Time frame: After 7 nights of clear lenses

Population: Participants who complete both phases

ArmMeasureValue (MEAN)Dispersion
Blue Blocking (BB)Pittsburgh Insomnia Rating Scale-65 (PIRS65) Total Score88.93 units on a scaleStandard Deviation 33.19
Secondary

Sleep Efficiency (Time Spent Asleep Divided by Total Time in Bed) Determined With Wrist-worn Accelerometry

Wrist-worn accelerometry gives an estimate of time spent asleep, time spent in bed, and sleep efficiency can be calculated from this. Sleep efficiency is calculated as time spent asleep divided by total time in bed. Here, we considered the mean calculated sleep efficiency over each 7-day treatment period.

Time frame: After 7 nights of BB lenses

Population: Participants who completed both phases

ArmMeasureValue (MEAN)Dispersion
Blue Blocking (BB)Sleep Efficiency (Time Spent Asleep Divided by Total Time in Bed) Determined With Wrist-worn Accelerometry78.35 % of total sleep timeStandard Deviation 9
Secondary

Sleep Efficiency (Time Spent Asleep Divided by Total Time in Bed) Determined With Wrist-worn Accelerometry

Wrist-worn accelerometry gives an estimate of time spent asleep, time spent in bed, and sleep efficiency can be calculated from this. Sleep efficiency is calculated as time spent asleep divided by total time in bed. Here, we considered the mean calculated sleep efficiency over each 7-day treatment period.

Time frame: After 7 nights of clear lenses

Population: Participants who completed both phases

ArmMeasureValue (MEAN)Dispersion
Blue Blocking (BB)Sleep Efficiency (Time Spent Asleep Divided by Total Time in Bed) Determined With Wrist-worn Accelerometry77.01 % of total sleep timeStandard Deviation 8.67

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026